Cancer Family
Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000045Explore in graph →
Non-malignant207 active trials6 approved drugs6 evidence items
- NCIt
- C7337
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000045Explore in graph →
Clinical trials
887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 |
| clinicaltrials |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT05702944 | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | recruiting | Phase 4 | 24 | Seoul National University HospitalOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | recruiting | Phase 2 | 28 | West China HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04905706 | 3D Laparoscopic Adrenalectomies for Adrenal Tumors | recruiting | — | 300 | Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06587802 | Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma | recruiting | Phase 2 | 18 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05563467 | Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.(PEMBR-01) | recruiting | Phase 2 | 24 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04127552 | Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations(ITACA) | recruiting | — | 68 | University of Roma La SapienzaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03976999 | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers(BCBOvaire) | recruiting | N/A | 300 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05200260 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | recruiting | Phase 2 | 220 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06803251 | The Role of the Vascular Surgeon in Oncologic Surgery of Abdominal and Pelvic Retroperitoneal Masses(IOVA-rpt) | recruiting | — | 70 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06801340 | Assessment of Metabolic Complications in Patients With Adrenal Tumors Through Radiological Images | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | recruiting | Phase 2 | 105 | Qilu Hospital of Shandong UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05718726 | Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI)(OPSI) | recruiting | — | 300 | Hampshire Hospitals NHS Foundation TrustOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06444607 | Hereditary Pheochromocytoma Assessment of Tumour Immunologies(HEPHESTOS) | recruiting | — | 200 | Radboud University Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05913427 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)(PESETA) | recruiting | Phase 2 | 80 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06436846 | Genomic Risk in Retroperitoneal Sarcoma | recruiting | — | 50 | Fox Chase Cancer CenterOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05991856 | Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma | recruiting | — | 45 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05912972 | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | recruiting | — | 13,500 | Asan Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03983226 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | recruiting | Phase 2 | 167 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04834544 | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care | recruiting | Phase 2 | 75 | Peking University Third HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03344016 | Multicenter Pheochromocytoma and Paraganglioma Evaluation(MUPPET) | recruiting | N/A | 1,148 | Felix BeuschleinOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03838718 | REtroperitoneal SArcoma Registry: an International Prospective Initiative(RESAR) | recruiting | — | 2,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 11 | Feb 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2025source: clinicaltrials